To complement the results from previous studies, our results
should be interpreted that the choice of statin be considered
not only on the basis of potency of cholesterol-lowering
effect but also glucose metabolism. In our study results, rosuvastatin
and atorvastatin showed different patterns of change in
HbA1c. The atorvastatin group tended to be changed to more
intensive DM therapy. At 6 months, HbA1c levels showed a
statistically significant difference between groups, and that
would have influenced physicians’ behavior to change the in-